Urothelial Carcinoma: Symptoms, Diagnosis, and Treatment Options

Introduction

Urothelial carcinoma, also known as transitional cell carcinoma, is the most common type of bladder cancer. It originates in the urothelial cells that line the bladder, ureters, and parts of the kidneys. While it affects both men and women, it is more prevalent in men. This article provides a comprehensive overview of urothelial carcinoma, covering risk factors, symptoms, diagnostic tests, treatment options, and home care strategies. Understanding this condition can help patients make informed decisions about their health and treatment. By breaking down complex medical information into simple terms, this article aims to empower you to discuss your condition confidently with healthcare providers.

What is Urothelial Carcinoma?

Urothelial carcinoma is a cancer that affects the lining of the urinary system. This article will explore its risk factors, symptoms, diagnostic tests, medications, procedures, and home care strategies to help manage symptoms.

Description of Urothelial Carcinoma

Urothelial carcinoma begins in the urothelial cells, which line the bladder, ureters, and renal pelvis (the part of the kidney that collects urine). These cells stretch and contract as the bladder fills and empties. When they become cancerous, tumors can form, potentially invading deeper layers of the bladder wall or spreading to other parts of the body.

The progression of urothelial carcinoma varies. In its early stages, the cancer is often confined to the bladder’s inner lining (non-invasive). If untreated, it can grow into the muscle layer (invasive) and spread to nearby organs or distant parts of the body (metastatic). Early detection is key to improving outcomes.

According to the American Cancer Society, bladder cancer is the fourth most common cancer in men and the eighth most common in women in the U.S. Urothelial carcinoma accounts for about 90% of all bladder cancers. The average age of diagnosis is around 73 years, and it is more common in older adults. While the exact cause is not always clear, several risk factors have been identified.

Risk Factors for Developing Urothelial Carcinoma

Lifestyle Risk Factors

Several lifestyle factors increase the risk of developing urothelial carcinoma. Smoking is the most significant, as it exposes the bladder to harmful chemicals filtered from the bloodstream and concentrated in the urine. Smokers are three times more likely to develop bladder cancer than non-smokers. Occupational exposure to chemicals, such as those used in the dye, rubber, leather, and textile industries, also raises the risk. These chemicals, known as aromatic amines, can be absorbed into the body and reach the bladder, potentially causing cancerous changes in the urothelial cells.

Other lifestyle factors include chronic bladder irritation from repeated urinary tract infections (UTIs) or long-term catheter use. A diet high in processed meats and low in fruits and vegetables may also increase the risk of bladder cancer.

Medical Risk Factors

Certain medical conditions and treatments can raise the risk of urothelial carcinoma. A history of bladder cancer or other urinary tract cancers increases the likelihood of recurrence. Radiation therapy in the pelvic area for cancers like prostate or cervical cancer also raises the risk. Additionally, chemotherapy drugs like cyclophosphamide, used to treat various cancers, can increase the risk of bladder cancer.

Chronic bladder inflammation, such as that caused by interstitial cystitis or schistosomiasis (a parasitic infection), can lead to changes in the bladder lining that increase cancer risk. Patients with diabetes who take pioglitazone for more than a year may also have an elevated risk of developing bladder cancer.

Genetic and Age-Related Risk Factors

Genetics and age significantly influence the development of urothelial carcinoma. The risk increases with age, with most cases occurring in people over 55. Men are more likely to develop bladder cancer than women, though the reasons are not entirely clear. Family history also plays a role—individuals with close relatives who have had bladder cancer may be at higher risk.

In rare cases, inherited genetic mutations, such as those affecting the retinoblastoma (RB1) gene or the PTEN gene, can increase the risk of bladder cancer. People with Lynch syndrome, a genetic condition that raises the risk of several cancers, may also be more likely to develop urothelial carcinoma.

Clinical Manifestations of Urothelial Carcinoma

Hematuria

Hematuria, or blood in the urine, is the most common symptom of urothelial carcinoma, occurring in about 85% of patients. It can be visible (gross hematuria) or detected only through a urine test (microscopic hematuria). The tumor disrupts the bladder or urinary tract lining, leading to bleeding. This symptom is often painless, which may delay diagnosis as patients might not seek immediate medical attention. Hematuria is more common in the early stages but can persist or worsen as the cancer progresses.

Urinary Frequency

Urinary frequency, or the need to urinate more often than usual, affects about 30% of patients with urothelial carcinoma. This occurs when the tumor irritates the bladder lining, reducing its capacity to hold urine. Patients may feel the urge to urinate more frequently, even if only small amounts of urine are passed. Urinary frequency is more common in patients with bladder tumors and may be more pronounced in advanced stages.

Urinary Urgency

Urinary urgency, the sudden and strong need to urinate, affects about 25% of patients with urothelial carcinoma. Like urinary frequency, urgency occurs when the tumor irritates the bladder wall, causing it to contract more frequently. This symptom can be distressing, as it may lead to accidents or a constant need to find a bathroom. Urgency is often seen in patients with bladder tumors and can worsen as the tumor grows.

Dysuria

Dysuria, or painful urination, affects about 20% of patients with urothelial carcinoma. This occurs when the tumor causes inflammation or irritation in the bladder or urethra, leading to discomfort or a burning sensation during urination. Dysuria is more common in advanced disease or when tumors are located near the urethra. It can also indicate infection, which may occur alongside the cancer.

Flank Pain

Flank pain, or pain in the side between the ribs and hip, affects about 10% of patients with urothelial carcinoma. This symptom is more common in advanced stages, especially when the tumor has spread to the kidneys or ureters. Flank pain can result from urinary tract obstruction, causing urine to back up into the kidneys, leading to swelling and discomfort.

Pelvic Pain

Pelvic pain affects about 15% of patients with advanced or invasive urothelial carcinoma. This pain occurs when the tumor grows into surrounding tissues or organs, such as the muscles or bones of the pelvis. Pelvic pain can be constant or intermittent and may worsen with movement or pressure. It often indicates that the cancer has spread beyond the bladder or urinary tract.

Weight Loss

Unexplained weight loss affects about 10% of patients, typically in advanced stages of urothelial carcinoma. Cancer can cause weight loss by increasing metabolism and reducing appetite. In some cases, the tumor may cause nausea or difficulty eating, further contributing to weight loss. This symptom often indicates that the cancer has spread to other parts of the body.

Fatigue

Fatigue, or persistent tiredness, affects around 20% of patients with urothelial carcinoma. Cancer-related fatigue can result from the body’s immune response to the tumor or from anemia, a common complication of cancer. Fatigue can also stem from the emotional and physical toll of dealing with cancer and its treatments. This symptom worsens as the disease progresses and can significantly impact quality of life.

Anemia

Anemia, or a low red blood cell count, affects about 15% of patients with urothelial carcinoma. It can result from chronic blood loss due to hematuria or from the cancer itself, which may interfere with red blood cell production. Anemia can cause fatigue, weakness, and shortness of breath. It is more common in advanced stages and may require treatment with blood transfusions or medications to boost red blood cell production.

Back Pain

Back pain affects about 10% of patients with advanced urothelial carcinoma. This symptom can occur when the tumor spreads to the bones or nerves in the spine, causing pain and discomfort. Back pain may also result from urinary tract obstruction, leading to swelling and pressure in the kidneys. Like pelvic pain, back pain often indicates that the cancer has spread beyond the bladder or urinary tract.

Diagnostic Evaluation of Urothelial Carcinoma

Diagnosing urothelial carcinoma typically begins with a review of the patient’s symptoms and medical history, followed by a physical examination. However, several diagnostic tests are usually required to confirm the diagnosis. These tests help visualize the bladder and urinary tract, detect cancer cells, and determine the extent of the disease. Early detection is crucial for improving outcomes, so if you experience any symptoms of urothelial carcinoma, seek medical attention promptly. Below are the most common diagnostic tests used to evaluate urothelial carcinoma.

Cystoscopy

Test Information

Cystoscopy allows doctors to directly visualize the bladder and urethra using a thin, flexible tube called a cystoscope. The cystoscope, equipped with a camera and light, transmits images to a monitor. During the procedure, the cystoscope is inserted through the urethra into the bladder. Typically performed under local anesthesia, cystoscopy is a key diagnostic tool for urothelial carcinoma, as it allows doctors to see abnormal growths or tumors inside the bladder.

Results that Indicate Urothelial Carcinoma

During cystoscopy, the doctor looks for abnormal growths, lesions, or tumors in the bladder. A tumor may appear as a raised, irregular mass or a flat, red patch on the bladder lining. The doctor may take a biopsy (a small tissue sample) to confirm the presence of cancer cells. If no abnormalities are seen, it does not completely rule out urothelial carcinoma, especially if symptoms persist. Additional tests, such as imaging or cytology, may be recommended to further evaluate the urinary tract.

Urinary Cytology

Test Information

Urinary cytology examines urine samples for abnormal or cancerous cells. This non-invasive test involves collecting a urine sample, which is then analyzed under a microscope by a pathologist. Urinary cytology is particularly useful for detecting high-grade urothelial carcinoma, as cancer cells often shed into the urine. However, it may not be as effective in detecting low-grade tumors, which may not shed as many cells. This test is often used alongside other diagnostic tools, such as cystoscopy or imaging, to confirm a diagnosis.

Results that Indicate Urothelial Carcinoma

If abnormal or cancerous cells are found in the urine sample, this may indicate urothelial carcinoma. High-grade cancer cells tend to appear larger and more irregular than normal cells, with abnormal nuclei. If the test results are positive, further diagnostic tests, such as a biopsy or imaging, will be needed to confirm the diagnosis and determine the extent of the disease. If the test is negative but symptoms persist, additional testing may still be necessary, as urinary cytology is not always able to detect low-grade tumors.

CT Scan

Test Information

A CT (computed tomography) scan uses X-rays to create detailed cross-sectional images of the body. For urothelial carcinoma, a CT scan of the abdomen and pelvis is often performed to visualize the bladder, kidneys, and urinary tract. The test may involve a contrast dye, injected into a vein to highlight abnormalities. A CT scan is important for diagnosing urothelial carcinoma because it can detect tumors, assess their size and location, and determine whether the cancer has spread to nearby organs or lymph nodes.

Results that Indicate Urothelial Carcinoma

If a CT scan shows a mass or thickening of the bladder wall, this may indicate urothelial carcinoma. The scan can also reveal whether the cancer has spread to other parts of the body, such as the lymph nodes, liver, or lungs. If the CT scan is negative but symptoms persist, further testing, such as a cystoscopy or biopsy, may be needed to rule out other conditions or detect smaller tumors that may not be visible on the scan.

MRI

Test Information

An MRI (magnetic resonance imaging) scan uses powerful magnets and radio waves to create detailed images of the body’s internal structures. Unlike a CT scan, MRI does not use radiation. For urothelial carcinoma, an MRI of the abdomen and pelvis may be performed to assess the bladder and surrounding tissues. MRI is particularly useful for evaluating the extent of the tumor and determining whether it has invaded nearby muscles or organs. This test may also be used to assess the lymph nodes and detect any metastasis (spread of cancer) to other parts of the body.

Results that Indicate Urothelial Carcinoma

An MRI scan can show the size, shape, and location of a tumor, as well as whether it has spread to nearby tissues or organs. If the scan reveals a mass or abnormal thickening of the bladder wall, this may indicate urothelial carcinoma. MRI is especially helpful in determining the stage of the cancer, which is important for treatment planning. If the MRI results are negative but symptoms persist, additional tests, such as a biopsy or urinary cytology, may be needed to confirm the diagnosis.

What if All Tests are Negative but Symptoms Persist?

If all diagnostic tests come back negative but you continue to experience symptoms such as hematuria, urinary urgency, or pelvic pain, it’s important to follow up with your healthcare provider. Persistent symptoms may indicate another underlying condition, such as a urinary tract infection, kidney stones, or interstitial cystitis. In some cases, additional testing or a second opinion may be necessary to rule out urothelial carcinoma or other serious conditions. Your healthcare provider will work with you to determine the next steps in your evaluation and care.

Treatment Options for Urothelial Carcinoma

Medications for Urothelial Carcinoma

Atezolizumab

Atezolizumab is an immunotherapy drug that blocks the PD-L1 protein, which allows cancer cells to hide from the immune system. By inhibiting this protein, Atezolizumab helps the immune system recognize and attack cancer cells more effectively.

This medication is typically used in patients with advanced or metastatic urothelial carcinoma, especially when chemotherapy has failed or is not an option. It is administered intravenously, usually every few weeks.

Some patients may experience gradual symptom improvement, including tumor shrinkage or slowed disease progression. However, responses vary, and regular monitoring is essential.

Pembrolizumab

Pembrolizumab is another immunotherapy drug that targets the PD-1 receptor on immune cells, enhancing the body’s ability to fight cancer. Like Atezolizumab, it helps the immune system recognize and destroy cancer cells.

Pembrolizumab is often used in advanced urothelial carcinoma, particularly when other treatments, such as chemotherapy, have not been effective. It is given as an intravenous infusion every three weeks.

Patients may experience tumor reduction and slower disease progression. Response times vary, but some patients see improvement within a few months.

Nivolumab

Nivolumab is an immunotherapy drug that blocks the PD-1 protein, similar to Pembrolizumab. By doing so, it helps the immune system attack cancer cells more effectively.

Nivolumab is used in patients with advanced urothelial carcinoma who have not responded to chemotherapy. It is administered intravenously, typically every two to four weeks.

Patients may experience tumor shrinkage and improved survival rates. However, it may take several months to see significant changes, and not all patients respond to the treatment.

Gemcitabine

Gemcitabine is a chemotherapy drug that interferes with the DNA of cancer cells, preventing them from growing and dividing.

It is often used in combination with other chemotherapy agents, such as Cisplatin, for treating advanced or metastatic urothelial carcinoma. It is administered intravenously in cycles, usually every three weeks.

Patients may experience tumor shrinkage and slower disease progression. Side effects can include fatigue, nausea, and a weakened immune system.

Cisplatin

Cisplatin is a platinum-based chemotherapy drug that damages the DNA of cancer cells, leading to their death.

It is commonly used as a first-line treatment for urothelial carcinoma, especially in combination with other drugs like Gemcitabine. Cisplatin is given intravenously in cycles.

Patients may experience significant tumor shrinkage, but side effects such as kidney damage, hearing loss, and nausea are common. Regular monitoring is essential to manage these risks.

Carboplatin

Carboplatin is another platinum-based chemotherapy drug, similar to Cisplatin, but with fewer side effects, particularly on the kidneys.

It is often used in patients who cannot tolerate Cisplatin due to its toxicity. Carboplatin is administered intravenously in cycles, often in combination with other chemotherapy drugs.

Patients may experience tumor shrinkage and slower disease progression, though the response may be less robust than with Cisplatin.

Docetaxel

Docetaxel is a chemotherapy drug that disrupts the microtubules in cancer cells, preventing them from dividing and growing.

It is typically used in patients with advanced urothelial carcinoma who have not responded to other treatments. Docetaxel is administered intravenously in cycles.

Patients may experience tumor size reduction, but side effects such as fatigue, hair loss, and low blood cell counts are common.

Vinflunine

Vinflunine is a chemotherapy drug that inhibits the formation of microtubules, which are essential for cancer cell division.

It is often used in patients with advanced urothelial carcinoma who have not responded to first-line chemotherapy. Vinflunine is administered intravenously in cycles.

Patients may experience slower disease progression, though side effects such as fatigue, nausea, and low blood counts are common.

Mitomycin C

Mitomycin C is a chemotherapy drug that works by cross-linking DNA strands, preventing cancer cells from replicating.

It is often used as an intravesical therapy, meaning it is delivered directly into the bladder, for treating non-muscle invasive urothelial carcinoma.

Patients may experience reduced tumor recurrence, but side effects such as bladder irritation and urinary symptoms are common.

Doxorubicin

Doxorubicin is a chemotherapy drug that interferes with the DNA of cancer cells, preventing them from growing and dividing.

It is sometimes used in combination with other chemotherapy agents for treating advanced urothelial carcinoma. Doxorubicin is administered intravenously in cycles.

Patients may experience tumor shrinkage, but side effects such as heart damage, nausea, and hair loss are common.

Procedures for Urothelial Carcinoma

Cystectomy

A cystectomy is a surgical procedure that involves the removal of the bladder. In some cases, nearby organs may also be removed.

This procedure is typically used in patients with muscle-invasive urothelial carcinoma or when other treatments have failed. It can be a partial or radical cystectomy, depending on the extent of the cancer.

Patients may experience a significant reduction in cancer risk, but the procedure requires lifestyle adjustments, such as the use of a urostomy bag or neobladder.

Transurethral Resection (TURBT)

Transurethral resection of bladder tumor (TURBT) is a minimally invasive procedure used to remove tumors from the bladder lining.

This procedure is often used for non-muscle invasive urothelial carcinoma and can be both diagnostic and therapeutic. It is performed using a cystoscope inserted through the urethra.

Patients can expect tumor size reduction and may require follow-up treatments to prevent recurrence. Recovery is generally quick, with minimal side effects.

Nephroureterectomy

A nephroureterectomy is a surgical procedure that involves the removal of the kidney and ureter, often used when urothelial carcinoma affects the upper urinary tract.

This procedure is typically reserved for patients with high-grade or invasive cancer in the kidney or ureter. It can be performed laparoscopically or through open surgery.

Patients may experience a significant reduction in cancer risk, but the loss of a kidney may impact overall kidney function, requiring careful monitoring.

Improving Urothelial Carcinoma Outcomes and Seeking Medical Help

While medical treatments are essential for managing urothelial carcinoma, certain lifestyle changes can improve overall health and potentially enhance treatment outcomes. Staying hydrated helps flush toxins from the body, while a diet rich in fruits, vegetables, and antioxidants supports the immune system. Regular exercise, even light activities like walking, can boost energy levels and reduce stress.

Avoiding tobacco and limiting alcohol consumption are crucial, as both can increase the risk of cancer recurrence. Managing stress through techniques like meditation or yoga, getting adequate sleep, and maintaining a healthy weight are also beneficial. Some patients may explore herbal supplements, but it’s essential to consult a healthcare provider before starting any new supplements, as they may interact with cancer treatments.

Telemedicine offers a convenient way to discuss these lifestyle changes and monitor your condition without the need for in-person visits. If you notice any new or worsening symptoms, such as blood in the urine or unexplained weight loss, seek medical help promptly.

Living with Urothelial Carcinoma: Tips for Better Quality of Life

Living with urothelial carcinoma can be challenging, but there are ways to improve your quality of life. Staying informed about your condition and treatment options can help you feel more in control. Joining support groups, either in person or online, can provide emotional support and practical advice from others going through similar experiences.

Maintaining open communication with your healthcare team is crucial. Don’t hesitate to ask questions or express concerns about your treatment or side effects. Telemedicine can make it easier to stay in touch with your doctors, allowing you to manage your condition from the comfort of your home.

Conclusion

Urothelial carcinoma is a serious condition, but with early diagnosis and appropriate treatment, many patients can manage their symptoms and improve their quality of life. Treatment options range from chemotherapy and immunotherapy to surgical procedures, depending on the stage and severity of the cancer.

Early detection is key to improving outcomes, so it’s important to seek medical advice if you experience any symptoms. Our telemedicine practice offers a convenient way to discuss your concerns, receive a diagnosis, and explore treatment options without the need for in-person visits. Don’t wait—reach out to us today to take the first step toward managing your health.

James Kingsley

Learn More